MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
There is now clear evidence of improved biochemical disease free survival (bDFS) with radiotherapy dose-escalation in all prostate cancer (PCa) risk groups [1,2]. Despite the advent of new techniques, external beam radiotherapy (EBRT) is limited in dose escalation due to the continuous change in the position, shape and volume of the target volume as well as the organs at risk (OARs). High-dose-rate brachytherapy (HDR) is a recommended treatment of eligible patients with prostate cancer as a method of dose escalation in conjunction with external beam radiation therapy according to the American Society of Clinical Oncology& Cancer Care Ontario guidelines [3].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Yasir Alayed, Laura D'Alimonte, Joelle Helou, Ananth Ravi, Gerard Morton, Hans T. Chung, Masoom Haider, Merrylee McGuffin, Liying Zhang, Andrew Loblaw Tags: Original Article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Clinical Trials | External Beam Therapy | Prostate Cancer | Radiation Therapy | Radiology | Study